Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 7/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | TP53 | P04637 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL242283 | 0.98 | LOXL2 (0.70) | LOXL2NPC1RAB9AMAPTTP53 | |
| SCHEMBL4482992 | 0.84 | LOXL2 (1.00) | LOXL2NPC1RAB9AMAPTTP53 | |
| SCHEMBL155002 | 0.83 | MAPT (1.00) | LOXL2NPC1RAB9AMAPTTP53 | |
| SCHEMBL1420033 | 0.83 | TP53 (0.81) | LOXL2NPC1RAB9AMAPTTP53 | |
| Hydrochloric Acid SCHEMBL28542524 | 0.82 | LOXL2 (0.96) | LOXL2NPC1RAB9AMAPTTP53 | |
| SCHEMBL10796782 | 0.81 | LOXL2 (0.80) | LOXL2NPC1RAB9AMAPTTP53 | |
| SCHEMBL2125047 | 0.79 | NPC1 (0.70) | LOXL2NPC1RAB9AMAPTTP53 | |
| SCHEMBL622536 | 0.79 | NPC1 (0.70) | LOXL2NPC1RAB9AMAPTTP53 | |
| SCHEMBL2621291 | 0.79 | MAPT (0.70) | LOXL2NPC1RAB9AMAPTTP53 | |
| SCHEMBL9642061 | 0.79 | MAPT (0.84) | LOXL2NPC1RAB9AMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042902-B1 | METHOD FOR PRODUCING ENDO-9-AZABICYCLO[3.3.1]NONAN-3-OL DERIVATIVE | NIPPON SODA CO (JP) | 2018-10-10 | — | — | EP | claimed |
| US-9896451-B2 | Method for producing endo-9-azabicyclo[3.3.1]nonan-3-ol derivative | NIPPON SODA CO., LTD. (JP) | 2018-02-20 | — | — | US | claimed |
| US-20160200726-A1 | METHOD FOR PRODUCING ENDO-9-AZABICYCLO[3.3.1]NONAN-3-OL DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2016-07-14 | — | — | US | claimed |
| EP-3042902-A1 | METHOD FOR PRODUCING ENDO-9-AZABICYCLO[3.3.1]NONANE-3-OL DERIVATIVE | Nippon Soda Co., Ltd. (JP) | 2016-07-13 | — | — | EP | claimed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | claimed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | claimed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | claimed |
| EP-0712403-B1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1997-09-10 | — | — | EP | claimed |
| JP-54030161-A | — | — | None | — | — | JP | disclosed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12600719-B2 | Salt inducible kinase inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4660192-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-1993017025-A1 | 3-SUBSTITUTED IMIDAZO(1,5-A)QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY | THE UPJOHN COMPANY (US) | 1993-09-02 | — | — | WO | disclosed |
| WO-1992022552-A1 | IMIDAZO[1,5-a]QUINOXALINES | THE UPJOHN COMPANY (US) | 1992-12-23 | — | — | WO | disclosed |
| CN-85104453-A | Prepare a kind of method that is used for the treatment of the tetrahydro naphthols of hypertension | — | 1986-12-10 | — | — | CN | disclosed |
| EP-0163458-A1 | Tetrahydronaphthalenols for the treatment of hypertension | E.R. Squibb & Sons, Inc. (US) | 1985-12-04 | — | — | EP | disclosed |
| JP-S5430161-A | 2-AMINOMETHYLBENZOXAZOLES AND THEIR PHARMACEUTICALLY ACCEPTABLE ACID SALTS | MITSUBISHI CHEM IND LTD | 1979-03-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200726-A1 | METHOD FOR PRODUCING ENDO-9-AZABICYCLO[3.3.1]NONAN-3-OL DERIVATIVE | CYP8B1, CYP2C9, HAAO | LOXL2 2392/4885NPC1 3138/4885RAB9A 44/4885 |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | LOXL2 4056/4885NPC1 1316/4885RAB9A 4538/4885 |
| US-12600719-B2 | Salt inducible kinase inhibitors | GRK6, SGK1, CSNK1A1 | LOXL2 2132/4885NPC1 1164/4885RAB9A 1970/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | LOXL2 4486/4885NPC1 896/4885RAB9A 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.